Skip to content

Swiss Chinese Law Association — Geneva

SCLA | Swiss Chinese Law Association

Legal Observatory / Investment and Business

Legal Update China Hong Kong SAR Draft legislation

Hong Kong Medical Device Advisory Panel Holds Inaugural Meeting on Proposed Statutory Regulatory Regime

The Medical Device Advisory Panel under the Hong Kong Department of Health held its inaugural meeting to advise on establishing a statutory regulatory regime for medical devices.

What Changed

  • The Medical Device Advisory Panel, chaired by Professor Philip Chiu, held its inaugural meeting on November 19, 2026.
  • The legislative proposal aligns with the First Five-Year Plan (2026-2030) and the 2026 Policy Address to establish the Centre for Medical Products Regulation.
  • The Panel endorsed six principles for legislative reform, including mandatory licensing for upstream supply chain traders and risk-based tiered device registration.

The Medical Device Advisory Panel (Advisory Panel) under the Department of Health (DH) of Hong Kong SAR held its inaugural meeting on November 19, 2026. The Advisory Panel convened to provide expert advice on the Government's ongoing work to establish a new statutory regulatory regime for medical devices supplied in Hong Kong.

Chaired by Professor Philip Chiu, the Advisory Panel comprises representatives from the medical, engineering, and innovation and technology sectors. Its establishment aligns with strategic objectives stated in The First Five-Year Plan for Economic and Social Development of the Hong Kong Special Administrative Region (2026-2030) and The Chief Executive's 2026 Policy Address. These policy frameworks direct the Government to intensify regulatory reforms for drugs and medical devices, establish the Centre for Medical Products Regulation, and position Hong Kong as an international health and medical innovation hub.

During the meeting, DH representatives presented a review of the existing Medical Device Administrative Control System (MDACS)—which has operated on a voluntary basis for over 20 years—alongside the Government's legislative proposal. The Advisory Panel fully supported advancing the legislative reform based on six core principles:

1. Safeguarding public safety and health;

2. Promoting innovation;

3. Aligning with international regulatory standards;

4. Building on local experience under the voluntary MDACS;

5. Focusing on control at source by requiring upstream traders in the supply chain to obtain licences; and

6. Implementing tiered registration of medical devices in an orderly manner based on risk management principles.

In addition to gathering stakeholder feedback on the statutory framework, the Advisory Panel will advise the DH on the ongoing operation and transitional arrangements for the voluntary MDACS. The proposed regime aims to cover pre-market and post-market risk management stages to ensure device safety, quality, and performance across Hong Kong.

Who May Be Affected

Upstream traders in the medical device supply chain, medical device manufacturers, distributors, healthcare professionals, and technology innovators operating in or supplying Hong Kong SAR.

Cross-Border Context

The proposed statutory framework aims to align Hong Kong SAR's medical device regulation with international standards, affecting cross-border medical device suppliers and supporting Hong Kong's development into an international health and medical innovation hub.

What to check next

  • Monitor the Department of Health's Medical Device Division website for member details and legislative updates.
  • Track future announcements regarding public consultation dates and draft legislation details for the statutory medical device regime.

This article provides general information and does not constitute legal advice. Consult the official text and obtain advice appropriate to your circumstances where needed.

Keep the issues that matter to you in view

Subscribe to SCLA updates and choose your interests.